Skip to main content
//empty //empty
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 13.73
Day High 14.05
Open:14.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
- CNW Group - Thu Sep 3, 12:30PM CDT
CNW Group - CMTX
Thu Sep 3, 12:30PM CDT
HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
VASCEPA� (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
- CNW Group - Mon Aug 31, 5:30AM CDT
CNW Group - CMTX
Mon Aug 31, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announced today that the trial results from Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: Final results of the EVAPORATE Trial were presented at ESC Congress 2020, the annual meeting of the European Society of Cardiology, on August 29, 2020, by Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months. As referenced below, these final results can be found in the concurrent publication in European Heart Journal.
HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
- CNW Group - Fri Aug 7, 5:30AM CDT
CNW Group - CMTX
Fri Aug 7, 5:30AM CDT
HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 13.73 +0.58% increase
on 09/21/20
Period Open:16.30
Price movement based on the high, low and last over the given period.
17.18 -19.62% decrease
on 08/27/20
-2.49 (-15.28%) decrease
since 08/21/20
3-Month 13.73 +0.58% increase
on 09/21/20
Period Open:19.75
Price movement based on the high, low and last over the given period.
19.23 -28.19% decrease
on 06/23/20
-5.94 (-30.08%) decrease
since 06/19/20
52-Week 13.73 +0.58% increase
on 09/21/20
Period Open:14.83
Price movement based on the high, low and last over the given period.
25.92 -46.72% decrease
on 12/31/19
-1.02 (-6.88%) decrease
since 09/20/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies